COVID-19 Drug Developed to Reduce Death Rate by 50 Percent

Influencing the whole world for 2 years COVID-19 The fight against the war continues at full speed without slowing down. With each passing day, a new treatment and drug is being developed against COVID-19. The name we hear the most Pfizer-BioNTech, Sinovac, Sputnik V and modernIn addition to the vaccine treatments of AstraZenecaagainst the COVID-19 virus antibody cocktail developed.

Achieved the desired success from late-stage clinical trials AZD7442 It increases the risk of severe COVID-19 and related death in patients who have symptoms for seven days or less but are not hospitalized. 50 percent rate was reduced.

AZD7442 could play an important role in the fight against COVID-19

British pharmaceutical company injection This new treatment administered through; After many tests, it is used both in the treatment of COVID-19 and against the disease. take precautions It was recorded as the first of its kind, showing successful results on behalf of the company. AstraZeneca, from two antibodies Even with vaccines, the drug, which is a cocktail consisting of not having enough immunity or due to other reasons immunosuppressed He stated that it was developed to support people. If the duration of action of the drug long-term expected to be.

Working as a principal investigator in the company Hugh Montgomeryregarding the test results of the drug “These positive results suggest that an appropriate intramuscular dose of AZD7442 is being used to combat this devastating epidemic. an important role He shows that he can play.” he said.

In addition to the drug, AstraZeneca, which has a widely used COVID-19 vaccine around the world, last week announced that AZD7442, one of the US regulators, was used as a preventive treatment. request permission had been found.

More than 900 volunteer adults participated in the testing of the drug.

worldwide 13 to the test studies of the cocktail tested in the country; half is AstraZeneca, the other half placebo received 900More than 1,000 volunteer adults participated.

AZD7442; in case of infection keeping the virus in the body It consists of lab-made antibodies specially designed to stall for months. Vice President of AstraZeneca Mene Pangolos; He underlined that a serious success can be achieved against COVID-19 by providing an early intervention and protection of more than six months thanks to the antibody therapy they produce.

On the other hand, other treatments such as AZD1442 belonging to the class of monoclonal antibodies regeneron, Eli Lilly and GlaxoSmithKline (GSK) previously developed and available in the USA mild to moderate It was approved for the treatment of COVID-19 cases. One of these drugs, Regeneron, is against symptomatic infection in the first week. 72 percent, after which 93 percent while providing protection; The drug produced by GSK-Vir as a result of a joint study is at risk of hospitalization and death. 79 percentIt had a reduction of . The treatment produced by Eli Lilly, on the other hand, has a greater effect on the disease compared to placebo. 70 percenthad a success.